Real-world Uptake of Enfortumab Vedotin plus Pembrolizumab after US Food and Drug Administration Approval Among Patients with Advanced Urothelial Cancer

IF 25.3 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2024-11-01 DOI:10.1016/j.eururo.2024.08.012

Ronac Mamtani , Ernesto Ulloa-Pérez , Ravi B. Parikh , Khilna Patel , Blanca Homet Moreno , Chethan Ramamurthy , Haojie Li , Rebecca A. Hubbard

引用次数: 0

查看原文本刊更多论文

美国食品药品管理局批准 Enfortumab Vedotin 加 Pembrolizumab 用于晚期尿路上皮癌患者后的实际使用情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.